Human plasma-derived coagulation factor VIII concentrate, naturally stabilised with von Willebrand factor (VWF)

Packshot of octanate®

octanate® is indicated for treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) of all age groups. This preparation is not indicated for von Willebrand disease.



Available in vials of 250 IU, 500 IU and 1000 IU.


Key features of octanate® 
Over 20 years of clinical experience:
  • Proven efficacy and safety profile in the treatment and prevention of bleeding in patients of all ages with haemophilia A1.

Effective inhibitor removal, even in patients with poor prognosis for ITI success2:
  • Inhibitors eliminated in 79.2% of patients in median time of 3.9 months;

  • Complete ITI success in 71% patients in a median time of 10.9 months;

  • 86% reduction in mean monthly bleeding rate after inhibitor elimination.

In 48 patients in an interim analysis of the ObsITI study2

Efficacy and reassuring incidence of inhibitors in previously untreated patients (PUPs)3:
  • 90% of PUPs inhibitor free;

  • No inhibitors in patients with non-null F8 mutations;

  • Haemostatic efficacy rated as “excellent” in 99.6% of infusions;

  • Haemostatic efficacy rated as “excellent” in 100% of surgical procedures.

In 51 PUPs treated with octanate® in a prospective study3


1. octanate Summary of Product Characteristics.
2. Kreuz W et al. Haemophilia 2016; 22:87-95.
3. Klukowska A et al. Haemophilia 2018; 24:211-8.


You are now on Octapharma’s global website. Please select your country from the menu at the top of this page to access more detailed country-specific information or to contact your local Octapharma team.